4.8 Article

Visualizing myocardial inflammation in a rat model of type 4 cardiorenal syndrome by dual-modality molecular imaging

Journal

BIOMATERIALS
Volume 68, Issue -, Pages 67-76

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2015.07.050

Keywords

Type 4 cardiorenal syndrome; Myocardial inflammation; Cardiovascular imaging; Nanoparticle; Iron oxide nanoparticle; Optical imaging

Funding

  1. Major State Basic Research Development Program of China (973 Program) [2013CB733802, 2010CB933903]
  2. National Nature Science Foundation of China (NSFC) [81371538, 81230034, 81101139]
  3. Jiangsu Provincial Special Program of Medical Science [BL2013029]
  4. British Heart Foundation [PG/14/19/30751] Funding Source: researchfish

Ask authors/readers for more resources

Type 4 cardiorenal syndrome (CRS) is a life-threatening world health problem in which chronic kidney disease leads to progressive cardiovascular disease. In type 4 CRS, cardiac inflammation is an excellent target for both detection and therapy; however, this progression was underestimated by previous studies due to the lack of effective detection methods. To noninvasively visualize cardiac inflammation and monitor therapeutic efficacy of anti-inflammatory treatment in type 4 CRS, we here synthesized a dualmodality magneto-fluorescent nanoparticle (MNP) by combining ultrasmall superparamagnetic iron oxide nanoparticle and Rhodamine B for both magnetic resonance imaging (MRI) and optical imaging. This dual-functional MNP exhibited excellent performance such as high r2 relaxivity coefficient (283.4 mM(-1) s(-1)), high magnetism (96.7 emu/g iron) and a near neutral surface charge to minimize the reticuloendothelial system uptake. In vivo cardiac MRI showed significant negative contrast in the type 4 CRS rats, and the signal intensity on optical imaging was significantly higher in the type 4 CRS group compared with sham-operated and drug-treated groups. The specific targeting profile of MNPs to monocyte-macrophages was proven by histopathological analysis. Taken together, we demonstrate that this dual-modality strategy is feasible for noninvasively assessing myocardial inflammation and monitoring therapeutic efficacy in type 4 CRS. (C) 2015 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available